TY - JOUR
T1 - Use of molecular maging markers of glycolysis, hypoxia and proliferation (18F-FDG, 64Cu-ATSM and 18F-FLT) in a dog with fibrosarcoma
T2 - the importance of individualized treatment planning and monitoring
AU - Zornhagen, Kamilla Westarp
AU - Clausen, Malene Martini
AU - Hansen, Anders E.
AU - Law, Ian
AU - McEvoy, Fintan
AU - Engelholm, Svend Aage
AU - Kjær, Andreas
AU - Kristensen, Annemarie Thuri
PY - 2015/9/11
Y1 - 2015/9/11
N2 - Glycolysis, hypoxia, and proliferation are important factors in the tumor microenvironment contributing to treatment-resistant aggressiveness. Imaging these factors using combined functional positron emission tomography and computed tomography can potentially guide diagnosis and management of cancer patients. A dog with fibrosarcoma was imaged using 18F-FDG, 64Cu-ATSM, and 18F-FLT before, during, and after 10 fractions of 4.5 Gy radiotherapy. Uptake of all tracers decreased during treatment. Fluctuations in 18F-FDG and 18F-FLT PET uptakes and a heterogeneous spatial distribution of the three tracers were seen. Tracer distributions partially overlapped. It appears that each tracer provides distinct information about tumor heterogeneity and treatment response.
AB - Glycolysis, hypoxia, and proliferation are important factors in the tumor microenvironment contributing to treatment-resistant aggressiveness. Imaging these factors using combined functional positron emission tomography and computed tomography can potentially guide diagnosis and management of cancer patients. A dog with fibrosarcoma was imaged using 18F-FDG, 64Cu-ATSM, and 18F-FLT before, during, and after 10 fractions of 4.5 Gy radiotherapy. Uptake of all tracers decreased during treatment. Fluctuations in 18F-FDG and 18F-FLT PET uptakes and a heterogeneous spatial distribution of the three tracers were seen. Tracer distributions partially overlapped. It appears that each tracer provides distinct information about tumor heterogeneity and treatment response.
U2 - 10.3390/diagnostics5030372
DO - 10.3390/diagnostics5030372
M3 - Journal article
C2 - 26854160
SN - 2075-4418
VL - 5
SP - 372
EP - 382
JO - Diagnostics
JF - Diagnostics
IS - 3
ER -